Our Top 10 Research Initiatives of 2024
This year, the Kidney Cancer Association made headway on multiple research initiatives across a range of focus areas. Here are our top 10 achievements in 2024.
Research Breakthroughs
Patient-Centered HRQOL Measures for mRCC – Through KCA funding, Dr. Cristiane Bergerot of Grupo Oncoclinicas in Brazil has developed a patient-centered health-related quality of life (HRQOL) measure tailored to metastatic renal cell carcinoma (mRCC) patients. This initiative ensures that patient-reported outcomes, often overlooked in research, are integrated into care delivery. By prioritizing patient needs and experiences, this tool enhances care strategies and supports quality of life improvements.
Single-Cell mtDNA Dynamics in Tumor Research – Supported by a KCA Young Investigator Award, Dr. Ed Reznik of Memorial Sloan Kettering Cancer Center published a study in Nature Genetics exploring the co-regulation of nuclear and mitochondrial genomes in tumors at the single-cell level. This cutting-edge research provides a foundational understanding of tumor biology, paving the way for highly targeted therapies and potential breakthroughs in personalized medicine for kidney cancer patients.
Pathogenic Role of RNASET2 in Clear Cell RCC – KCA-funded investigator Dr. Brandon Manley of Moffitt Cancer Center has uncovered the pathogenic roles of RNASET2 in clear cell renal cell carcinoma, the most common RCC subtype. This research identifies novel mechanisms underlying the disease, creating opportunities for innovative therapeutic approaches that could improve survival and overall patient outcomes.
Collaborative Research and Innovation
Think Tank: Coalition for a Cure – Collaborative forums have united international experts to address key challenges, prioritize research, and advance clinical care in kidney cancer, identifying research gaps for the KCA to target.
Access to AI tools and data to Fuel RCC Advancements – A partnership with philanthropic donors and Tempus focuses on analyzing clinico-genomic data in RCC, chromophobe RCC, and Native American populations to uncover disparities and refine care strategies.
Innovative Research Projects Funded by KCA – Six KCA-funded research initiatives have tackled critical topics, including rare subtypes like chromophobe RCC, translocation RCC, and the impact of microplastics on cancer, driving novel approaches to kidney cancer treatment and understanding.
Advancing Care Through Connection
Mentorship Programs – The Kidney Cancer Association Mentorship Academy (KCAMA) and the Dr. Nizar Tannir Rare Kidney Cancer Scholar program connect early-career oncologists with expert mentors, fostering expertise and next-generation leadership in the kidney cancer field.
Women in RCC Initiative – This initiative empowers women physicians in kidney cancer through mentorship, networking, and professional development, showcasing their leadership and research contributions. It has grown from a handful of physicians to over 100 participants.
Expanded KCA Research Partnerships – Collaborations with organizations like the Cancer Research Institute, American Brain Tumor Association, Chromophobe and Oncocytic Tumor Alliance, American Association for Cancer Research, and co-organizing kidney cancer sessions at events like the 2024 European Multidisciplinary Congress on Urological Cancers have amplified research, advocacy, education, and patient support efforts.
Celebrating 25 Years of IKCS – The KCA celebrated 25 years of hosting International Kidney Cancer Symposiums, recognizing the organization’s role fostering collaboration and advancing cutting-edge research for the kidney cancer community with the theme “Bridges to Cure: Innovating Kidney Cancer Care.”